Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

TPEX:7427 Revenue

Great Novel Therapeutics Biotech & Medicals had revenue of 5.63M TWD in the half year ending June 30, 2026, with 967.55% growth. This brings the company's total for the last twelve months to 6.21M, up 248.57% year-over-year. In the year 2025, Great Novel Therapeutics Biotech & Medicals had annual revenue of 1.21M, down -28.49%. That makes Great Novel Therapeutics Biotech & Medicals the 45,535th largest company in the world by revenue and 2,190th in Taiwan.

• Revenue (ttm): 6.21M
• Revenue Growth: +248.57%
• P/S Ratio: 494.37
• Revenue / Employee: 269.91K
• Employees: 23
• Market Cap: 3.07B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.21M	-480.00K	-28.49%
Dec 31, 2024	1.69M	-3.17M	-65.26%
Dec 31, 2023	4.85M	4.31M	798.15%
Dec 31, 2022	540.00K	-90.00K	-14.29%
Dec 31, 2021	630.00K	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 2, 2026

Data Sources Report a data error